News

The first proof-of-concept trial is designed to study effects of the humanized antibody in subjects with renal cell carcinoma (RCC). RCC patients who failed the standard of care

The marketing authorization received for Vesomni is related to the "treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic

The FDA had approved Diclegis as the only treatment for nausea and vomiting of pregnancy (NVP) when conservative management fails. Duchesnay USA chief executive officer Gilbert Godin said

Details of the transaction have not been revealed, however, it is expected that the 725,000ft² property would be handed over by Merck on 28 June 2013. The consortium

The patent claims describe methods of preparing an immunologically-active adjuvant-bound, thermostable, freeze dried vaccine composition that uses conventional adjuvants comprised of aluminum salts, in addition to claims covering

R-Tech is trialing RU-101 ophthalmic solution as a severe dry eye therapy. Novozymes Biopharma marketing director Dermot Pearson said, "Novozymes is dedicated to supporting our customers in the

Focused on advancing the proprietary diagnostic technology, originally developed by Lilly, the collaboration agreement is part of Corgenix’ expanded contract services business unit for the healthcare and biotechnology

The company submitted a biologics license application (BLA) to the FDA for its pegylated subcutaneous injectable candidate developed for relapsing forms of multiple sclerosis. The BLA application included

Development of the new antibiotics will receive funding through a public-private partnership. For the initial period of 18 months, HHS will provide $40m and around $200m upon the